SEC Comment Letter 0000000000-24-009669 to Coherus BioSciences, Inc. (CHRS) (CIK 0001512762) (CHRS)
Coherus BioSciences, Inc. (CHRS) (CIK 0001512762)
Date: Aug. 23, 2024 · CIK: 0001512762 · Accession: 0000000000-24-009669
AI Filing Summary & Sentiment
File numbers found in text: 001-36721
Letter
August 23, 2024 Dennis M. Lanfear President and Chief Executive Officer Coherus BioSciences, Inc. 333 Twin Dolphin Drive, Suite 600 Redwood City, California 94065 Re:Coherus BioSciences, Inc. Definitive Proxy Statement on Schedule 14A Filed April 15, 2024 File No. 001-36721 Dear Dennis M. Lanfear: We have limited our review of your most recent definitive proxy statement to those issues we have addressed in our comment. Please respond to this letter by providing the requested information and/or confirming that you will revise your future proxy disclosures in accordance with the topics discussed below. If you do not believe a comment applies to your facts and circumstances, please tell us why in your response. After reviewing your response to this letter, we may have additional comments. Definitive Proxy Statement on Schedule 14A Pay Versus Performance, page 63 1.We note footnotes 4 and 5 to your pay versus performance table calculates total shareholder return and peer group total shareholder return using a measurement point of December 31, 2020. Please note that for calculating total shareholder return and peer group total shareholder return, the “’measurement period’ must be the period beginning at the ‘measurement point’ established by the market close on the last trading day before the registrant's earliest fiscal year in the table.” Please ensure your measurement period uses the correct measurement point for calculating total shareholder return and peer group total shareholder return. Refer to Item 402(v)(2)(iv) of Regulation S-K. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.
August 23, 2024 Page 2 Please contact Jennifer Gowetski at 202-551-3401 or Daniel Crawford at 202-551-7767 with any questions. Sincerely, Division of Corporation Finance Disclosure Review Program cc:Max Brunner, Esq.
Show Raw Text
August 23, 2024
Dennis M. Lanfear
President and Chief Executive Officer
Coherus BioSciences, Inc.
333 Twin Dolphin Drive, Suite 600
Redwood City, California 94065
Re:Coherus BioSciences, Inc.
Definitive Proxy Statement on Schedule 14A
Filed April 15, 2024
File No. 001-36721
Dear Dennis M. Lanfear:
We have limited our review of your most recent definitive proxy statement to those issues
we have addressed in our comment.
Please respond to this letter by providing the requested information and/or confirming that
you will revise your future proxy disclosures in accordance with the topics discussed below. If
you do not believe a comment applies to your facts and circumstances, please tell us why in your
response.
After reviewing your response to this letter, we may have additional comments.
Definitive Proxy Statement on Schedule 14A
Pay Versus Performance, page 63
1.We note footnotes 4 and 5 to your pay versus performance table calculates total
shareholder return and peer group total shareholder return using a measurement point of
December 31, 2020. Please note that for calculating total shareholder return and peer
group total shareholder return, the “’measurement period’ must be the period beginning at
the ‘measurement point’ established by the market close on the last trading day before the
registrant's earliest fiscal year in the table.” Please ensure your measurement period uses
the correct measurement point for calculating total shareholder return and peer group total
shareholder return. Refer to Item 402(v)(2)(iv) of Regulation S-K.
We remind you that the company and its management are responsible for the accuracy and
adequacy of their disclosures, notwithstanding any review, comments, action or absence of action
by the staff.
August 23, 2024
Page 2
Please contact Jennifer Gowetski at 202-551-3401 or Daniel Crawford at 202-551-7767
with any questions.
Sincerely,
Division of Corporation Finance
Disclosure Review Program
cc:Max Brunner, Esq.